Strategies for the Identification of T Cell-Recognized Tumor Antigens in Hematological Malignancies for Improved Graft-versus-Tumor Responses after Allogeneic Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 6, 2015, Pages 1000-1007

  Zilberberg, Jenny ^a   Feinman, Rena ^a   Korngold, Robert ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Blood and marrow transplantation; Hematological malignancy; Minor histocompatibility antigens; Tumor vaccination; Tumor associated antigens; Tumor specific antigens

Indexed keywords

MINOR HISTOCOMPATIBILITY ANTIGEN; PEPTIDE; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CANCER VACCINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN EXPRESSION; BLOOD DONOR; BLOOD TRANSFUSION; CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; GENETIC ASSOCIATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TECHNIQUE; INTESTINE; LIVER; NONHUMAN; REVIEW; SKIN; T LYMPHOCYTE; ADOPTIVE TRANSFER; ALLOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; GENETICS; GRAFT VERSUS TUMOR EFFECT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; PATHOLOGY; TRANSPLANTATION; TREATMENT OUTCOME;

ADOPTIVE TRANSFER; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BIOMARKERS; BONE MARROW TRANSPLANTATION; CANCER VACCINES; GRAFT VS TUMOR EFFECT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MINOR HISTOCOMPATIBILITY ANTIGENS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84930518751     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.11.001     Document Type: Review

References (104)

1. Zeidan A.M., Forde P.M., Symons H., et al. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2014, 20:314-318.
2. Luznik L., Fuchs E.J. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 2002, 9:123-137.
3. Kolb H.J., Simoes B., Schmid C. Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies. Curr Opin Oncol 2004, 16:167-173.
4. Zorn E., Wang K.S., Hochberg E.P., et al. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Clin Cancer Res 2002, 8:2052-2060.
5. Alyea E.P., DeAngelo D.J., Moldrem J., et al. NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2010, 16:1037-1069.
6. Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979, 300:1068-1073.
7. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
8. Blazar B.R., Korngold R., Vallera D.A. Recent advances in graft-versus-host disease (GVHD) prevention. Immunol Rev 1997, 157:79-109.
9. Korngold R. Biology of graft-vs.-host disease. Am J Pedtr Hematol Oncol 1993, 15:18-27.
10. Korngold R., Sprent J. Graft-versus-host disease in experimental allogeneic bone marrow transplantation. Proc Soc Exp Biol Med 1991, 197:12-18.
11. Borrello I.M., Sotomayor E.M. Cancer vaccines for hematologic malignancies. Cancer Control 2002, 9:138-151.
12. Oostvogels R., Minnema M.C., van Elk M., et al. Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1. Leukemia 2013, 27:642-649.
13. Spaapen R., Mutis T. Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease. Best Pract Res Clin Haematol 2008, 21:543-557.
14. Parmiani G., De Filippo A., Novellino L., Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol 2007, 178:1975-1979.
15. Kessler J.H., Melief C.J. Identification of T-cell epitopes for cancer immunotherapy. Leukemia 2007, 21:1859-1874.
16. Bocchia M., Defina M., Aprile L., Sicuranza A. Peptide vaccines for hematological malignancies: a missed promise?. Int J Immunol 2014, 99:107-116.
17. van der Bruggen P., Traversari C., Chomez P., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
18. Traversari C., van der Bruggen P., Luescher I.F., et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992, 176:1453-1457.
19. Costa F.F., Le Blanc K., Brodin B. Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells 2007, 25:707-711.
20. Kalejs M., Erenpreisa J. Cancer/testis antigens and gametogenesis: a review and "brain-storming" session. Cancer Cell Int 2005, 5:4.
21. Kronig H., Hofer K., Conrad H., et al. Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity. Int J Cancer 2009, 125:649-655.
22. Boel P., Wildmann C., Sensi M.L., et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995, 2:167-175.
23. de Carvalho F., Vettore A.L., Colleoni G.W. Cancer/testis antigen MAGE-C1/CT7: new target for multiple myeloma therapy. Clin Devel Immunol 2012, 2012:257695.
24. Anderson L.D., Cook D.R., Yamamoto T.N., et al. Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. Cancer Immunol Immunother 2011, 60:985-997.
25. Hernandez J., Garcia-Pons F., Lone Y.C., et al. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci U S A 2002, 99:12275-12280.
26. Friedrichs B., Siegel S., Andersen M.H., et al. Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies. Leuk Lymphoma 2006, 47:978-985.
27. Andersen M.H., thor S.P. Survivin-a universal tumor antigen. Histol Histopathol 2002, 17:669-675.
28. Knights A.J., Weinzierl A.O., Flad T., et al. A novel MHC-associated proteinase 3 peptide isolated from primary chronic myeloid leukaemia cells further supports the significance of this antigen for the immunotherapy of myeloid leukaemias. Leukemia 2006, 20:1067-1072.
29. Fujiwara H., El Ouriaghli F., Grube M., et al. Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase. Blood 2004, 103:3076-3083.
30. Oka Y., Elisseeva O.A., Tsuboi A., et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 2000, 51:99-107.
31. Oka Y., Udaka K., Tsuboi A., et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 2000, 164:1873-1880.
32. Apostolopoulos V., McKenzie I.F. Cellular mucins: targets for immunotherapy. Crit Rev Immunol 1994, 14:293-309.
33. Matsushita M., Yamazaki R., Ikeda H., Kawakami Y. Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies. Leuk Lymphoma 2003, 44:439-444.
34. Arai J., Yasukawa M., Ohminami H., et al. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 2001, 97:2903-2907.
35. Rezvani K., Yong A.S., Tawab A., et al. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 2009, 113:2245-2255.
36. Kessler J.H., Beekman N.J., Bres-Vloemans S.A., et al. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 2001, 193:73-88.
37. Greiner J., Schmitt M., Li L., et al. Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood 2006, 108:4109-4117.
38. Greiner J., Ringhoffer M., Simikopinko O., et al. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp Hematol 2000, 28:1413-1422.
39. Lacey S.F., La Rosa C., Kaltcheva T., et al. Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice. Blood 2011, 118:2159-2169.
40. Molldrem J., Dermime S., Parker K., et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996, 88:2450-2457.
41. Anguille S., Van Tendeloo V.F., Berneman Z.N. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 2012, 26:2186-2196.
42. Cheever M.A., Allison J.P., Ferris A.S., et al. The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res 2009, 15:5323-5337.
43. Van Driessche A., Berneman Z.N., Van Tendeloo V.F. Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist 2012, 17:250-259.
44. Maslak P.G., Dao T., Krug L.M., et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010, 116:171-179.
45. Brossart P., Schneider A., Dill P., et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res 2001, 61:6846-6850.
46. Burton J., Mishina D., Cardillo T., et al. Epithelial mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma. Clin Cancer Res 1999, 5:3065s-3072s.
47. Brossart P., Heinrich K.S., Stuhler G., et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999, 93:4309-4317.
48. Xing P.X., Apostolopoulos V., Trapani J., et al. Peptide epitopes in breast cancer mucins. Adv Exp Med Biol 1994, 353:9-16.
49. Andrulis M., Ellert E., Mandel U., et al. Expression of Mucin-1 in multiple myeloma and its precursors: correlation with glycosylation and subcellular localization. Histopathology 2014, 64:799-806.
50. Novellino L., Castelli C., Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005, 54:187-207.
51. Bleakley M., Riddell S.R. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 2004, 4:371-380.
52. Sherwood R.A., Brent L., Rayfield L.S. Presentation of alloantigens by host cells. Eur J Immunol 1986, 16:569-574.
53. Korngold R., Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med 1978, 148:1687-1698.
54. de Bueger M., Bakker A., Van Rood J.J., et al. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 1992, 149:1788-1794.
55. Warren E.H., Greenberg P.D., Riddell S.R. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood 1998, 91:2197-2207.
56. Marijt W.A., Heemskerk M.H., Kloosterboer F.M., et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A 2003, 100:2742-2747.
57. Mommaas B., Kamp J., Drijfhout J.W., et al. Identification of a novel HLA-B60-restricted T cell epitope of the minor histocompatibility antigen HA-1 locus. J Immunol 2002, 169:3131-3136.
58. den Haan J.M., Meadows L.M., Wang W., et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 1998, 279:1054-1057.
59. Dolstra H., de Rijke B., Fredrix H., et al. Bi-directional allelic recognition of the human minor histocompatibility antigen HB-1 by cytotoxic T lymphocytes. Eur J Immunol 2002, 32:2748-2758.
60. Brickner A.G., Evans A.M., Mito J.K., et al. The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood 2006, 107:3779-3786.
61. Spierings E., Kim Y.H., Hendriks M., et al. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013, 19:1244-1253.
62. van Bergen C.A., Kester M.G., Jedema I., et al. Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene. Blood 2007, 109:4089-4096.
63. de Rijke B., van Horssen-Zoetbrood A., Beekman J.M., et al. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest 2005, 115:3506-3516.
64. Feng X., Hui K.M., Younes H.M., Brickner A.G. Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses. Trends Immunol 2008, 29:624-632.
65. Hobo W., Broen K., van der Velden W.J., et al. Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2013, 19:274-282.
66. Goulmy E., Schipper R., Pool J., et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996, 334:281-285.
67. Lin M.T., Gooley T., Hansen J.A., et al. Absence of statistically significant correlation between disparity for the minor histocompatibility antigen-HA-1 and outcome after allogeneic hematopoietic cell transplantation. Blood 2001, 98:3172-3173.
68. Fanning S.L., Zilberberg J., Stein J., et al. Unraveling graft-versus-host disease and graft-versus-leukemia responses using TCR Vbeta spectratype analysis in a murine bone marrow transplantation model. J Immunol 2013, 190:447-457.
69. Wolpert E.Z., Grufman P., Sandberg J.K., et al. Immunodominance in the CTL response against minor histocompatibility antigens: interference between responding T cells, rather than with presentation of epitopes. J Immunol 1998, 161:4499-4505.
70. Wolpert E., Franksson L., Karre K. Dominant and cryptic antigens in the MHC class I restricted T cell response across a complex minor histocompatibility barrier: analysis and mapping by elution of cellular peptides. Int Immunol 1995, 7:919-928.
71. Sekimata M., Griem P., Egawa K., et al. Isolation of human minor histocompatibility peptides. Int Immunol 1992, 4:301-304.
72. de Bueger M., Verreck F., Blokland E., et al. Isolation of an HLA-A2.1 extracted human minor histocompatibility peptide. Eur J Immunol 1993, 23:614-618.
73. Kawakami Y., Fujita T., Matsuzaki Y., et al. Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Sci 2004, 95:784-791.
74. Warren E.H., Otterud B.E., Linterman R.W., et al. Feasibility of using genetic linkage analysis to identify the genes encoding T cell-defined minor histocompatibility antigens. Tissue Antigens 2002, 59:293-303.
75. Spaapen R.M., Lokhorst H.M., van den Oudenalder K., et al. Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis. J Exp Med 2008, 205:2863-2872.
76. Spaapen R.M., de Kort R.A., van den Oudenalder K., et al. Rapid identification of clinical relevant minor histocompatibility antigens via genome-wide zygosity-genotype correlation analysis. Clin Cancer Res 2009, 15:7137-7143.
77. Van Bergen C.A., Rutten C.E., Van Der Meijden E.D., et al. High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning. Cancer Res 2010, 70:9073-9083.
78. Griffioen M., Honders M.W., van der Meijden E.D., et al. Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity. Haematologica 2012, 97:1196-1204.
79. Siewert K., Malotka J., Kawakami N., et al. Unbiased identification of target antigens of CD8+ T cells with combinatorial libraries coding for short peptides. Nat Med 2012, 18:824-828.
80. Hombrink P., Hassan C., Kester M.G., et al. Discovery of T cell epitopes implementing HLA-peptidomics into a reverse immunology approach. J Immunol 2013, 190:3869-3877.
81. Maecker B., von B.-B., Anderson K.S., et al. Linking genomics to immunotherapy by reverse immunology-'immunomics' in the new millennium. Curr Mol Med 2001, 1:609-619.
82. Schuler M.M., Nastke M.D., Stevanovikc S. SYFPEITHI: database for searching and T-cell epitope prediction. Methods Mol Biol 2007, 409:75-93.
83. Schuler M.M., Donnes P., Nastke M.D., et al. SNEP: SNP-derived epitope prediction program for minor H antigens. Immunogenetics 2005, 57:816-820.
84. Shen W.J., Zhang S., Wong H.S. An effective and effecient peptide binding prediction approach for a broad set of HLA-DR molecules based on ordered weighted averaging of binding pocket profiles. Proteome Sci 2013, 11:S15.
85. Zhang L., Chen Y., Wong H.S., et al. TEPITOPEpan: extending TEPITOPE for peptide binding prediction covering over 700 HLA-DR molecules. PLoS One 2012, 7:e30483.
86. Popovic J., Li L.P., Kloetzel P.M., et al. The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed. Blood 2011, 118:946-954.
87. Hombrink P., Hadrup S.R., Bakker A., et al. High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations. PLoS One 2011, 6:e22523.
88. Larsen M.V., Lundegaard C., Lamberth K., et al. An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. Eur J Immunol 2005, 35:2295-2303.
89. Feldhahn M., Donnes P., Schubert B., et al. miHA-Match: computational detection of tissue-specific minor histocompatibility antigens. J Immunol Methods 2012, 386:94-100.
90. Nielsen M., Lundegaard C., Blicher T., et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PloS One 2007, 2:e796.
91. Robbins P.F., Lu Y.C., El-Gamil M., et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013, 19:747-752.
92. Ivanov R., Hol S., Aarts T.I., et al. T cell receptor-transgenic primary T cells as a tool for discovery of leukaemia-associated antigens. Clin Exp Immunol 2006, 143:78-84.
93. Willemsen R.A., Debets R., Chames P., Bolhuis R.L. Genetic engineering of T cell specificity for immunotherapy of cancer. Hum Immunol 2003, 64:56-68.
94. Friedman T.M., Goldgirsh K., Berger S.A., et al. Overlap between in vitro donor antihost and in vivo posttransplantation TCR Vbeta use: a new paradigm for designer allogeneic blood and marrow transplantation. Blood 2008, 112:3517-3525.
95. Jones S.C., Friedman T.M., Murphy G.F., Korngold R. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens. Biol Blood Marrow Transplant 2004, 10:91-105.
96. Margolis D.A., Casper J.T., Segura A.D., et al. Infiltrating T cells during liver graft-versus-host disease show a restricted T-cell repertoire. Biol Blood Marrow Transplant 2000, 6:408-415.
97. Liu C., He M., Rooney B., et al. Longitudinal analysis of T-cell receptor variable beta chain repertoire in patients with acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:335-345.
98. Patterson A.E., Korngold R. Infusion of select leukemia-reactive TCR Vbeta+ T cells provides graft-versus-leukemia responses with minimization of graft-versus-host disease following murine hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001, 7:187-196.
99. Friedman T.M., Jones S.C., Statton D., et al. Evolution of responding CD4+ and CD8+ T-cell repertoires during the development of graft-versus-host disease directed to minor histocompatibility antigens. Biol Blood Marrow Transplant 2004, 10:224-235.
100. Gerlinger M., Quezada S.A., Peggs K.S., et al. Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. J Pathol 2013, 231:424-432.
101. Emerson R.O., Sherwood A.M., Rieder M.J., et al. High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer. J Pathol 2013, 231:433-440.
102. Sherwood A.M., Emerson R.O., Scherer D., et al. Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue. Cancer Immunol Immunother 2013, 62:1453-1461.
103. Park T.S., Rosenberg S.A., Morgan R.A. Treating cancer with genetically engineered T cells. Trends Biotechnol 2011, 29:550-557.
104. Rezvani K. Posttransplantation vaccination: concepts today and on the horizon. Hematology Am Soc Hematol Educ Program 2011, 2011:299-304.